{"id":"W4321795635","doi":"10.1177/17588359231152843","title":"Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada)","funders":"National Cancer Institute; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Oncology; Placebo; Cancer; Hazard ratio; Clinical trial; Confidence interval; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007325589,0.0005267573,0.00273952,0.0003401358,0.0000839114,0.000003812692,0.0003823182,0.0003884418,0.0007616286],"category_scores_gemma":[0.0001814492,0.0003895655,0.0002148258,0.001519997,0.001226074,0.0002269644,0.00008118843,0.0005087343,0.00002080816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008122512,"about_ca_system_score_gemma":0.001403577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006269435,"about_ca_topic_score_gemma":0.004144311,"domain_scores_codex":[0.9952247,0.0004209315,0.001619727,0.0007013065,0.00123338,0.000800001],"domain_scores_gemma":[0.995541,0.002092537,0.001024322,0.0006239654,0.0002484908,0.0004696841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04871656,0.002594387,0.06100689,0.0006153692,0.0007843386,0.0001267534,0.003169883,0.003591788,0.001038259,0.0005346287,0.00000866717,0.8778125],"study_design_scores_gemma":[0.2597911,0.0602462,0.3574496,0.00494958,0.001709096,0.0006932796,0.01994865,0.004180342,0.01328768,0.01110481,0.2636362,0.003003481],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9652327,0.02057975,0.001591985,0.008743074,0.0007790687,0.001407825,0.000143514,0.0003023813,0.001219755],"genre_scores_gemma":[0.9763013,0.02039774,0.001449475,0.0009178669,0.0002349131,0.0004071979,0.00007014559,0.00008733965,0.0001340094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.874809,"threshold_uncertainty_score":0.9998556,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06506842105089145,"score_gpt":0.4343277424711693,"score_spread":0.3692593214202778,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}